Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-08-22
2006-08-22
Gupta, Anish (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S324000, C930S170000
Reexamination Certificate
active
07094755
ABSTRACT:
The present invention encompasses novel analogs of vasoactive intestinal peptide (VIP), containing substitutions at appropriately selected amino acids. The invention particularly relates to the design and synthesis of novel biologically active VIP analogs containing α, α-dialkylated amino acids in a site-specific manner. Specifically, the invention relates to the synthesis of VIP peptide derivatives, which bind selectively to VIP receptors on target cells. The invention encompasses methods for the generation of these peptides, compositions containing the peptides and the pharmacological applications of these peptides especially in the treatment and prevention of cancer.
REFERENCES:
patent: 4605641 (1986-08-01), Bolin et al.
patent: 4734400 (1988-03-01), Bolin et al.
patent: 4835252 (1989-05-01), Musso et al.
patent: 4866039 (1989-09-01), Wootton et al.
patent: 5141924 (1992-08-01), Bolin
patent: 5217953 (1993-06-01), Gozes et al.
patent: 5376637 (1994-12-01), Sawai et al.
patent: 5428015 (1995-06-01), Kurono et al.
patent: 5565424 (1996-10-01), Gozes et al.
patent: 5677419 (1997-10-01), Bolin et al.
patent: 5849261 (1998-12-01), Dean et al.
patent: 6007792 (1999-12-01), Dean et al.
patent: 0796867 (1997-09-01), None
patent: 796867 (1997-09-01), None
patent: 0835662 (1998-04-01), None
patent: 9830590 (1998-07-01), None
patent: 0005260 (2000-02-01), None
Jain, Rakesh, Delivery of Molecular Medicine to Solid Tumors, Science, vol. 271, pp. 1079-1080, Feb. 1996.
Dermer, Gerald. Another Anniversary for the War on Cancer, Bio/technology, vol. 12, p. 320 Mar. 1994.
Gura, Trisha. Systems for Identifying New Drugs Are Often Faulty, Science, vol. 278, pp. 1041-1042, Nov. 1997.
Golden, Fredrick. OF Mice and Men: Don't Blame the Rodents, Time, pp. 44, May 1998.
H. Frucht et al.; Characterization of Functional Receptors for Gastrointestinal Hormones on Human Colon Cancer Cells; Cancer Research 52; 1114-1122; Mar. 1, 1992.
Irene Virgolini et al.; Vasoactive Intestinal Peptide-Receptor Imagine for the Localization of Intestinal . . . Tumors; New England Journal of Medicine; vol. 331 (17); 1116-1121; Oct. 27, 1994.
G.Lilling et al.; Inhibition of Human Neuroblastoma Growth by a Specific VIP Antagonist; Journal of Molecular Neuroscience; vol. 5, 1994/1995; 231-239.
Gozes et al.; Vasoactive Intestinal Peptide Potentiates Sexual Behavior; Inhibition by Novel Antagonist Endocrinology; vol. 125, No. 6; 2945-2949; (1989).
Nokihara, K. et al. “Receptor Recognition of PACAP and VIP Examined by Binding Studies . . . ” Peptides, (1996) pp. 63-66.
Dickinson, T. et al. “VIP and PACAP: very important in pain?” TIPS, (1999) vol. 20, No. 8, pp. 324-329.
Scholz, Catherine C., et al;Correlation of Drug Response in Patients and in the Clonogenic Assay with Solid Human Tumour Xenografts;Eur. J. Cancer; vol. 26, No. 8 pp. 901-905, 1990.
Giovanella, Beppino, et al;Correlation Between Response to Chemotherapy of Human Tumors in Patients and in Nude Mice;Cancer 52, pp. 1146-1152, 1983.
Fiebig, H.H., et al.;Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discocery;European Journal of Cancer 40, pp. 802-820, 2004.
Johnson, JI, et al.;Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials;British Journal of Cancer; vol. 84; No. 10;pp. 1424-1431; 2001.
Burman Anand C.
Gupta Neena
Mathur Archna
Mukherjee Rama
Prasad Sudhanand
Dabur Research Foundation
Gupta Anish
Ladas and Parry LLP
LandOfFree
Vasoactive intestinal peptide analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vasoactive intestinal peptide analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vasoactive intestinal peptide analogs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3682321